NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and  Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs),